

Special Issue

Pharmacogenomics and Drug Metabolism: From Cytochrome P450 to Emerging Enzymatic Pathways

Message from the Guest Editor

This Special Issue welcomes original research, reviews, and short communications related to CYP450s and other drug-metabolizing enzymes. Topics of interest include enzyme discovery, substrate specificity, structural and functional analysis, redox partner interactions, enzyme engineering, inter-individual variability, and metabolic pathway reconstruction. We also welcome studies employing high-throughput screening platforms, model organisms, synthetic biology approaches, or recombinant expression systems (e.g., microbial cell factories), as well as studies that explore multi-omics integration (genomics, transcriptomics, proteomics), pharmacogenetic biomarker discovery, and computational or systems biology approaches for elucidating enzyme function and regulation. By encompassing the full spectrum of enzyme versatility, this Special Issue seeks to provide a comprehensive perspective on the evolving landscape of pharmacogenomics and drug metabolism research.

Guest Editor

Dr. Pradeepraj Durairaj

Department of Chemical and Biomedical Engineering, FAMU-FSU
College of Engineering, Florida State University, Tallahassee, FL 32310,
USA

Deadline for manuscript submissions

31 December 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/241529

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).